NASDAQ: HCM - Hutchison China MediTech Limited

Yield per half year: -2.75%
Sector: Healthcare

Download the report: word Word , pdf PDF

1. Summary

Advantages

  • Positive review The stock's return over the last year (39.81%) is higher than the sector average (-50.75%).
  • Positive review The company's current efficiency (ROE=15.03%) is higher than the sector average (ROE=11.82%)

Disadvantages

  • Negative review Price (18.72 $) is higher than fair price (6.49 $)
  • Negative review Dividends (0%) are below the sector average (1.871%).
  • Negative review Current debt level 6.73% has increased over 5 years from 5.02%.

2. Share price and performance

2.1. Share price

2.2. News

2.3. Market efficiency

Hutchison China MediTech Limited Healthcare Index
7 days -7.2% -100% -3.7%
90 days 19.5% -55.7% 2.8%
1 year 39.8% -50.7% 21.5%

Positive review HCM vs Sector: Hutchison China MediTech Limited has outperformed the "Healthcare" sector by 90.55% over the past year.

Positive review HCM vs Market: Hutchison China MediTech Limited has outperformed the market by 18.36% over the past year.

Positive review Stable price: HCM is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.

Long period: HCM with weekly volatility of 0.7655% over the past year.

3. Summary of the report

3.1. General

P/E: 29.07
P/S: 3.5

3.2. Revenue

EPS 0.5797
ROE 15.03%
ROA 8.73%
ROIC -25.43%
Ebitda margin 3.05%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Negative review Above fair price: The current price (18.72 $) is higher than the fair price (6.49 $).

Negative review Price is higher than fair: The current price (18.72 $) is 65.3% higher than the fair price.

4.2. P/E

Positive review P/E vs Sector: The company's P/E (29.07) is lower than that of the sector as a whole (89.01).

Positive review P/E vs Market: The company's P/E (29.07) is lower than that of the market as a whole (54.97).

4.2.1 P/E Similar companies

4.3. P/BV

Positive review P/BV vs Sector: The company's P/BV (3.94) is lower than that of the sector as a whole (49.73).

Negative review P/BV vs Market: The company's P/BV (3.94) is higher than that of the market as a whole (2.36).

4.3.1 P/BV Similar companies

4.4. P/S

Positive review P/S vs Sector: The company's P/S indicator (3.5) is lower than that of the sector as a whole (49.81).

Positive review P/S vs Market: The company's P/S indicator (3.5) is lower than that of the market as a whole (10).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

Negative review EV/Ebitda vs Sector: The company's EV/Ebitda (107.01) is higher than that of the sector as a whole (61.32).

Negative review EV/Ebitda vs Market: The company's EV/Ebitda (107.01) is higher than that of the market as a whole (22.83).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Ebitda

Negative review Yield Trend: Negative and has fallen by -33.96% over the last 5 years.

Positive review Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-33.96%).

Positive review Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-8.41%).

5.4. ROE

Positive review ROE vs Sector: The company's ROE (15.03%) is higher than that of the sector as a whole (11.82%).

Negative review ROE vs Market: The company's ROE (15.03%) is lower than that of the market as a whole (31.82%).

5.5. ROA

Positive review ROA vs Sector: The company's ROA (8.73%) is higher than that of the sector as a whole (6.99%).

Positive review ROA vs Market: The company's ROA (8.73%) is higher than that of the market as a whole (6.37%).

5.6. ROIC

Negative review ROIC vs Sector: The company's ROIC (-25.43%) is lower than that of the sector as a whole (13.31%).

Negative review ROIC vs Market: The company's ROIC (-25.43%) is lower than that of the market as a whole (10.68%).

6. Finance

6.1. Assets and debt

Positive review Debt level: (6.73%) is quite low in relation to assets.

Negative review Increasing debt: over 5 years, the debt has increased from 5.02% to 6.73%.

Positive review Debt Covering: The debt is covered by 85.42% from net profit.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Negative review Low yield: The dividend yield of the company 0% is below the average for the sector '1.871%.

7.2. Stability and increase in payments

Negative review Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Negative review Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Negative review Dividend Coverage: Current payments from income (122.45%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Positive review Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

No insider transactions have been recorded yet